首页 > 最新文献

Journal of Surgical Oncology最新文献

英文 中文
Reply to "Comment on 'Prognostic Impact of the Cholangiolar Component in Combined Hepatocellular-Cholangiocarcinoma: Insights From a Western Single-Center Study'". 对“肝细胞-胆管合并癌中胆管成分对预后的影响:来自西方单中心研究的见解”的评论
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-18 DOI: 10.1002/jso.28056
Gilton Marques Fonseca, Paulo Herman
{"title":"Reply to \"Comment on 'Prognostic Impact of the Cholangiolar Component in Combined Hepatocellular-Cholangiocarcinoma: Insights From a Western Single-Center Study'\".","authors":"Gilton Marques Fonseca, Paulo Herman","doi":"10.1002/jso.28056","DOIUrl":"https://doi.org/10.1002/jso.28056","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142854643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient and Surgeon Attitudes Toward Opportunistic Salpingectomy During Nongynecological Surgeries for the Prevention of Ovarian Cancer: A Qualitative Study. 患者和外科医生对预防卵巢癌的非妇科手术中机会性输卵管切除术的态度:定性研究。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-17 DOI: 10.1002/jso.28050
Carly C Tymm, Reena M Vattakalam, David R Flum, Jason D Wright, Katherine N Fischkoff

Background and objectives: Opportunity salpingectomy (OS), or prophylactic removal of the fallopian tubes during an operation for another indication, is broadly accepted as a risk-reduction strategy for ovarian cancer during gynecological operations. However, OS during nongynecological abdominal surgery is rare in the United States. A better understanding of surgeon and patient attitudes and perceived barriers to OS during nongynecological surgeries may facilitate implementation in the United States.

Study design: Qualitative interviews were conducted with general surgeons (n = 10), gynecologic surgeons (n = 10), and patients (n = 20) to assess perspectives and barriers towards OS during nongynecological surgeries. Interviews were transcribed and inductive analysis was carried out to identify themes and categorize responses using NVivo data analysis software.

Results: OS during nongynecological surgery was viewed favorably by most patients and surgeons interviewed. While patients emphasized the importance of raising awareness of OS, both subsets of surgeons highlighted coordination, counseling, and billing barriers that would need to be overcome for efficient implementation.

Conclusion: OS was positively accepted by both patients and surgeons in our cohort. Improved attention to the shared barriers to implementation from our study may facilitate OS implementation during nongynecological surgery in the United States.

背景和目的:机会输卵管切除术(OS),或在手术中为其他适应症预防性切除输卵管,被广泛接受为妇科手术中卵巢癌的降低风险策略。然而,在美国,非妇科腹部手术中发生OS是罕见的。更好地了解外科医生和患者的态度以及在非妇科手术中对OS的感知障碍可能有助于在美国实施。研究设计:对普通外科医生(n = 10)、妇科医生(n = 10)和患者(n = 20)进行定性访谈,以评估非妇科手术中出现OS的观点和障碍。对访谈进行转录,并使用NVivo数据分析软件进行归纳分析,以确定主题并对回答进行分类。结果:接受调查的大多数患者和外科医生对非妇科手术中的OS持赞成态度。虽然患者强调提高对OS的认识的重要性,但两组外科医生都强调了为了有效实施需要克服的协调、咨询和计费障碍。结论:本组患者和外科医生均积极接受手术。从我们的研究中提高对实施的共同障碍的关注可能有助于在美国非妇科手术中实施OS。
{"title":"Patient and Surgeon Attitudes Toward Opportunistic Salpingectomy During Nongynecological Surgeries for the Prevention of Ovarian Cancer: A Qualitative Study.","authors":"Carly C Tymm, Reena M Vattakalam, David R Flum, Jason D Wright, Katherine N Fischkoff","doi":"10.1002/jso.28050","DOIUrl":"https://doi.org/10.1002/jso.28050","url":null,"abstract":"<p><strong>Background and objectives: </strong>Opportunity salpingectomy (OS), or prophylactic removal of the fallopian tubes during an operation for another indication, is broadly accepted as a risk-reduction strategy for ovarian cancer during gynecological operations. However, OS during nongynecological abdominal surgery is rare in the United States. A better understanding of surgeon and patient attitudes and perceived barriers to OS during nongynecological surgeries may facilitate implementation in the United States.</p><p><strong>Study design: </strong>Qualitative interviews were conducted with general surgeons (n = 10), gynecologic surgeons (n = 10), and patients (n = 20) to assess perspectives and barriers towards OS during nongynecological surgeries. Interviews were transcribed and inductive analysis was carried out to identify themes and categorize responses using NVivo data analysis software.</p><p><strong>Results: </strong>OS during nongynecological surgery was viewed favorably by most patients and surgeons interviewed. While patients emphasized the importance of raising awareness of OS, both subsets of surgeons highlighted coordination, counseling, and billing barriers that would need to be overcome for efficient implementation.</p><p><strong>Conclusion: </strong>OS was positively accepted by both patients and surgeons in our cohort. Improved attention to the shared barriers to implementation from our study may facilitate OS implementation during nongynecological surgery in the United States.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of Socio-Environmental Burden and Inequality With Cancer Screening and Mortality. 社会环境负担和不平等与癌症筛查和死亡率的关系。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-17 DOI: 10.1002/jso.28039
Shahzaib Zindani, Mujtaba Khalil, Zayed Rashid, Abdullah Altaf, Selamawit Woldesenbet, Timothy M Pawlik

Background and objectives: Social and environmental injustice may influence accessibility and utilization of health resources, affecting outcomes of patients with cancer. We sought to assess the impact of socio-environmental inequalities on cancer screening and mortality rates for breast, colon, and cervical cancer.

Methods: Data on cancer screening and environmental justice index social and environmental ranking (SER) was extracted from the CDC PLACES and ATSDR, respectively. Mortality rates were extracted using CDC WONDER. Screening targets were defined by Healthy People 2030.

Results: Among census tracts, 14 659 were classified as "low," 29 534 as "moderate," and 15 474 as "high" SER (high SER denoting greater socioenvironmental injustice). Screening targets were achieved by 31.1%, 16.2%, and 88.6% of tracts for colon, breast, and cervical cancers, respectively. High SER tracts were much less likely to reach screening targets compared with low SER tracts for colon (OR: 0.06), breast (OR: 0.24), and cervical cancer (OR: 0.05) (all p < 0.001). Median mortality rates for low and high SER were 16.7, and 21.0, respectively, for colon, 13.4, 14.75, respectively, for breast, and 1.0, 1.6, respectively, for cervical cancer (all p < 0.05).

Conclusion: Socioenvironmental disparities negatively influence cancer screening and mortality, underscoring the need to reduce environmental injustices through measures like equitable cancer screening services.

背景和目的:社会和环境的不公正可能影响卫生资源的可及性和利用,影响癌症患者的预后。我们试图评估社会环境不平等对乳腺癌、结肠癌和宫颈癌的癌症筛查和死亡率的影响。方法:分别从CDC PLACES和ATSDR中提取癌症筛查和环境正义指数社会和环境排名(SER)数据。使用CDC WONDER提取死亡率。筛查目标由《健康人群2030》确定。结果:在人口普查区中,有14 659个被划分为“低”,29 534个被划分为“中等”,15 474个被划分为“高”(高SER表示更大的社会环境不公正)。结肠癌、乳腺癌和宫颈癌的筛查目标分别达到31.1%、16.2%和88.6%。在结肠癌(OR: 0.06)、乳腺癌(OR: 0.24)和宫颈癌(OR: 0.05)中,与低SER束相比,高SER束达到筛查目标的可能性要小得多(均为p)。结论:社会环境差异对癌症筛查和死亡率有负面影响,强调需要通过公平的癌症筛查服务等措施减少环境不公正。
{"title":"Association of Socio-Environmental Burden and Inequality With Cancer Screening and Mortality.","authors":"Shahzaib Zindani, Mujtaba Khalil, Zayed Rashid, Abdullah Altaf, Selamawit Woldesenbet, Timothy M Pawlik","doi":"10.1002/jso.28039","DOIUrl":"https://doi.org/10.1002/jso.28039","url":null,"abstract":"<p><strong>Background and objectives: </strong>Social and environmental injustice may influence accessibility and utilization of health resources, affecting outcomes of patients with cancer. We sought to assess the impact of socio-environmental inequalities on cancer screening and mortality rates for breast, colon, and cervical cancer.</p><p><strong>Methods: </strong>Data on cancer screening and environmental justice index social and environmental ranking (SER) was extracted from the CDC PLACES and ATSDR, respectively. Mortality rates were extracted using CDC WONDER. Screening targets were defined by Healthy People 2030.</p><p><strong>Results: </strong>Among census tracts, 14 659 were classified as \"low,\" 29 534 as \"moderate,\" and 15 474 as \"high\" SER (high SER denoting greater socioenvironmental injustice). Screening targets were achieved by 31.1%, 16.2%, and 88.6% of tracts for colon, breast, and cervical cancers, respectively. High SER tracts were much less likely to reach screening targets compared with low SER tracts for colon (OR: 0.06), breast (OR: 0.24), and cervical cancer (OR: 0.05) (all p < 0.001). Median mortality rates for low and high SER were 16.7, and 21.0, respectively, for colon, 13.4, 14.75, respectively, for breast, and 1.0, 1.6, respectively, for cervical cancer (all p < 0.05).</p><p><strong>Conclusion: </strong>Socioenvironmental disparities negatively influence cancer screening and mortality, underscoring the need to reduce environmental injustices through measures like equitable cancer screening services.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment On: "Assessment of Artificial Intelligence Chatbot Responses to Common Patient Questions on Bone Sarcoma". 评论:"人工智能聊天机器人对骨肉瘤常见患者问题的回应评估"。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-17 DOI: 10.1002/jso.28052
Mengyang Zhang, Xiao Ye
{"title":"Comment On: \"Assessment of Artificial Intelligence Chatbot Responses to Common Patient Questions on Bone Sarcoma\".","authors":"Mengyang Zhang, Xiao Ye","doi":"10.1002/jso.28052","DOIUrl":"https://doi.org/10.1002/jso.28052","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
De-Escalating Surgery in Merkel Cell Carcinoma With Clinical Nodal Disease. 对有临床结节病的梅克尔细胞癌进行去鳞手术
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-15 DOI: 10.1002/jso.28037
Neha Shafique, Emily Ertmann, Gabriella N Tortorello, Cimarron E Sharon, Giorgos C Karakousis, John T Miura

Background: Merkel cell carcinoma (MCC) is a radiosensitive aggressive skin cancer that spreads via the lymphatics. There is uncertainty regarding the optimal management of the nodal basin for patients with MCC with clinically positive nodes. We study the efficacy of single node excision (SNE) as an alternative to a therapeutic lymph node dissection (TLND) in patients with limited nodal disease.

Methods: We performed a retrospective cohort study of patients with MCC with clinical nodal disease who underwent resection in the form of either SNE or TLND using the National Cancer Database. The association between type of surgery and overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazards modeling.

Results: 1835 patients met all inclusion criteria with 281 patients undergoing SNE and the remainder undergoing TLND. Patients receiving SNE and TLND were equally likely to receive radiation to the nodal basin (SNE 44.5% vs. TLND 48.5%, p = 0.22). There was no difference in 5-year OS between patients who received SNE versus TLND (SNE 43.9% vs. TLND 44.7%, p = 0.36). This persisted in a multivariable Cox proportional hazards model in which receipt of SNE remained not significantly associated with survival after adjusting for clinical and treatment factors including receipt of radiation (Hazard Ratio [HR] 1.17, 95% CI 0.96-1.42, p = 0.11). In patients undergoing SNE with radiation, 5-year OS was 54.4% (95% CI 44.1-63.6).

Conclusions: TLND is not associated with a survival advantage over SNE. Further prospective study into patterns of recurrence and safety of SNE is needed.

背景:梅克尔细胞癌(MCC)是一种对放射线敏感的侵袭性皮肤癌,可通过淋巴管扩散。对于临床结节阳性的梅克尔细胞癌患者,结节盆地的最佳治疗方法尚不确定。我们研究了单结节切除术(SNE)作为治疗性淋巴结清扫术(TLND)的替代方案,对结节病变有限的患者的疗效:我们利用全国癌症数据库对临床上有结节病、接受了单结节切除术或治疗性淋巴结清扫术的 MCC 患者进行了一项回顾性队列研究。研究采用 Kaplan-Meier 法和 Cox 比例危险模型估算了手术类型与总生存期(OS)之间的关系:1835名患者符合所有纳入标准,其中281名患者接受了SNE手术,其余患者接受了TLND手术。接受SNE和TLND的患者接受结节盆地放射治疗的可能性相同(SNE 44.5% vs. TLND 48.5%, p = 0.22)。接受SNE和TLND的患者在5年生存率上没有差异(SNE 43.9% vs. TLND 44.7%,p = 0.36)。这种情况在多变量考克斯比例危险模型中依然存在,在调整了包括接受放射治疗在内的临床和治疗因素后,接受SNE与生存率仍无明显关系(危险比[HR] 1.17,95% CI 0.96-1.42,p = 0.11)。在接受放射治疗的 SNE 患者中,5 年 OS 为 54.4% (95% CI 44.1-63.6):结论:TLND与SNE相比不具有生存优势。需要对 SNE 的复发模式和安全性进行进一步的前瞻性研究。
{"title":"De-Escalating Surgery in Merkel Cell Carcinoma With Clinical Nodal Disease.","authors":"Neha Shafique, Emily Ertmann, Gabriella N Tortorello, Cimarron E Sharon, Giorgos C Karakousis, John T Miura","doi":"10.1002/jso.28037","DOIUrl":"https://doi.org/10.1002/jso.28037","url":null,"abstract":"<p><strong>Background: </strong>Merkel cell carcinoma (MCC) is a radiosensitive aggressive skin cancer that spreads via the lymphatics. There is uncertainty regarding the optimal management of the nodal basin for patients with MCC with clinically positive nodes. We study the efficacy of single node excision (SNE) as an alternative to a therapeutic lymph node dissection (TLND) in patients with limited nodal disease.</p><p><strong>Methods: </strong>We performed a retrospective cohort study of patients with MCC with clinical nodal disease who underwent resection in the form of either SNE or TLND using the National Cancer Database. The association between type of surgery and overall survival (OS) was estimated using the Kaplan-Meier method and Cox proportional hazards modeling.</p><p><strong>Results: </strong>1835 patients met all inclusion criteria with 281 patients undergoing SNE and the remainder undergoing TLND. Patients receiving SNE and TLND were equally likely to receive radiation to the nodal basin (SNE 44.5% vs. TLND 48.5%, p = 0.22). There was no difference in 5-year OS between patients who received SNE versus TLND (SNE 43.9% vs. TLND 44.7%, p = 0.36). This persisted in a multivariable Cox proportional hazards model in which receipt of SNE remained not significantly associated with survival after adjusting for clinical and treatment factors including receipt of radiation (Hazard Ratio [HR] 1.17, 95% CI 0.96-1.42, p = 0.11). In patients undergoing SNE with radiation, 5-year OS was 54.4% (95% CI 44.1-63.6).</p><p><strong>Conclusions: </strong>TLND is not associated with a survival advantage over SNE. Further prospective study into patterns of recurrence and safety of SNE is needed.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829082","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Pulmonary Metastasectomy for Non-Primary Lung Cancer: Umbrella Review of Meta-Analyses. 非原发性肺癌肺转移切除术的作用:Meta分析综述。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-15 DOI: 10.1002/jso.28033
Wongi Woo, Brandon Park, Awranoos Ahadi, Liam Il-Young Chung, Chan Mi Jung, Ankit Bharat, Young Kwang Chae

Background and objectives: Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the clinical outcomes of PM for non-primary lung cancer.

Methods: A systematic search for meta-analyses on PM for nonprimary lung cancers was conducted, encompassing publications up to January 3, 2024. This included seven primary cancers: renal cell, breast, adrenocortical, head and neck cancers, melanoma, germ cell tumors, and sarcoma. Overall survival and recurrence rates post-PM were assessed using random-effect models.

Results: This study included 16 systematic-review articles and 101 individual studies, involving 10 277 patients who underwent PM for nonprimary lung cancer. About half of the patients (47.1%) presented with multiple metastasis, and complete resection achieved in 87.2% [95% CI: 83.0-90.8]. The pooled 5-year overall survival rate post-PM was 41.2% [95%CI: 37.1%-45.4%]. Patients with germ cell tumors demonstrated higher survival rate (p < 0.05), while melanoma exhibited the worst outcome (p < 0.05). During follow-up, 57.6% [95% CI: 46.4-68.1] had recurrence; 48% of them had intrathoracic-only recurrence.

Conclusion: This study underscores the survival benefits associated with PM. Overall survival rates following PM did not differ based on primary cancer types. These findings highlight the importance of recognizing and incorporating PM into clinical practice when appropriate.

背景和目的:由于原发性癌症的异质性特征,肺转移切除术(PM)对非原发性肺癌的疗效尚未得到研究。本研究旨在调查非原发性肺癌肺转移切除术的临床疗效:方法:对非原发性肺癌肺转移切除术的荟萃分析进行了系统检索,包括截至 2024 年 1 月 3 日的出版物。其中包括七种原发性癌症:肾细胞癌、乳腺癌、肾上腺皮质癌、头颈部癌症、黑色素瘤、生殖细胞瘤和肉瘤。采用随机效应模型评估了PM后的总生存率和复发率:本研究包括16篇系统综述文章和101项个人研究,涉及10 277名接受PM治疗的非原发性肺癌患者。约半数患者(47.1%)出现多处转移,87.2%的患者实现了完全切除[95% CI:83.0-90.8]。PM术后5年总生存率为41.2%[95%CI:37.1%-45.4%]。生殖细胞肿瘤患者的生存率更高(P 结论:该研究强调了PM对患者生存的益处:这项研究强调了肿瘤切除术带来的生存益处。原发性癌症类型不同,预防性治疗后的总生存率也不尽相同。这些发现强调了认识到 PM 并在适当时将其纳入临床实践的重要性。
{"title":"The Role of Pulmonary Metastasectomy for Non-Primary Lung Cancer: Umbrella Review of Meta-Analyses.","authors":"Wongi Woo, Brandon Park, Awranoos Ahadi, Liam Il-Young Chung, Chan Mi Jung, Ankit Bharat, Young Kwang Chae","doi":"10.1002/jso.28033","DOIUrl":"https://doi.org/10.1002/jso.28033","url":null,"abstract":"<p><strong>Background and objectives: </strong>Due to heterogeneous characteristics of primary cancers, the efficacy of pulmonary metastasectomy (PM) in nonprimary lung cancers has not been investigated. This study aims to investigate the clinical outcomes of PM for non-primary lung cancer.</p><p><strong>Methods: </strong>A systematic search for meta-analyses on PM for nonprimary lung cancers was conducted, encompassing publications up to January 3, 2024. This included seven primary cancers: renal cell, breast, adrenocortical, head and neck cancers, melanoma, germ cell tumors, and sarcoma. Overall survival and recurrence rates post-PM were assessed using random-effect models.</p><p><strong>Results: </strong>This study included 16 systematic-review articles and 101 individual studies, involving 10 277 patients who underwent PM for nonprimary lung cancer. About half of the patients (47.1%) presented with multiple metastasis, and complete resection achieved in 87.2% [95% CI: 83.0-90.8]. The pooled 5-year overall survival rate post-PM was 41.2% [95%CI: 37.1%-45.4%]. Patients with germ cell tumors demonstrated higher survival rate (p < 0.05), while melanoma exhibited the worst outcome (p < 0.05). During follow-up, 57.6% [95% CI: 46.4-68.1] had recurrence; 48% of them had intrathoracic-only recurrence.</p><p><strong>Conclusion: </strong>This study underscores the survival benefits associated with PM. Overall survival rates following PM did not differ based on primary cancer types. These findings highlight the importance of recognizing and incorporating PM into clinical practice when appropriate.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Taxanes and Breast Cancer-Related Lymphedema. 紫杉烷与乳腺癌相关淋巴水肿。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-15 DOI: 10.1002/jso.28017
Daniel Najafali, Charalampos Siotos, George Kokosis
{"title":"Taxanes and Breast Cancer-Related Lymphedema.","authors":"Daniel Najafali, Charalampos Siotos, George Kokosis","doi":"10.1002/jso.28017","DOIUrl":"https://doi.org/10.1002/jso.28017","url":null,"abstract":"","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development and Validation of a Predictive Score for Preoperative Detection of Lymphovascular Invasion in Rectal Cancer. 直肠癌淋巴管侵犯术前检测预测评分的开发与验证
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-15 DOI: 10.1002/jso.28043
Sameh H Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Anjelli Wignakumar, Steven D Wexner

Background: Lymphovascular invasion (LVI) is an important prognosticator in rectal cancer (RC). We aimed to determine predictors for LVI in RC and incorporate them into a predictive risk score (PRS).

Methods: Case-control analysis of predictors of LVI in RC using data from a national database (2010-2019). Main outcome was LVI in RC and its predictors. Odds ratios of significant independent predictors of LVI were incorporated into a PRS.

Results: 55,178 patients were included (60.9% male; mean age: 61.3 years). LVI was detected in 10,446 (18.9%). Independent predictors were carcinomas that were signet-ring cell (OR: 1.98, p < 0.001), moderately differentiated (OR: 1.58, p < 0.001), poorly differentiated (OR: 3.9, p < 0.001), or undifferentiated carcinomas (OR: 4.1, p < 0.001), cN1 (OR: 1.21, p < 0.001), and cN2 (OR: 1.49, p < 0.001), stage and incorporated into a PRS (0-8). Incidence of LVI was 16.3% in the low-risk group, 27.8% in the intermediate-risk group, and 40.5% in the high-risk group (p < 0.001). The PPV of the score was 40.5%, NPV was 83.7%, accuracy was 82.4%, and specificity was 97.9%.

Conclusions: High-grade adenocarcinomas, signet-ring cell carcinomas, and lymph node involvement in clinical assessment were independently associated with LVI in RC. Incorporation of these predictors into a PRS conferred high specificity and good accuracy.

背景:淋巴血管浸润(LVI)是直肠癌(RC)的重要预后指标。我们的目的是确定RC中LVI的预测因子,并将其纳入预测风险评分(PRS)。方法:使用2010-2019年国家数据库数据,对RC中LVI的预测因素进行病例对照分析。主要观察指标为RC的LVI及其预测因子。LVI的显著独立预测因子的比值比被纳入PRS。结果:共纳入55,178例患者(男性60.9%;平均年龄:61.3岁)。LVI检出10446例(18.9%)。独立预测因子是印戒细胞癌(OR: 1.98, p)。结论:临床评估的高级别腺癌、印戒细胞癌和淋巴结累及与RC的LVI独立相关。将这些预测因素纳入PRS具有高特异性和良好的准确性。
{"title":"Development and Validation of a Predictive Score for Preoperative Detection of Lymphovascular Invasion in Rectal Cancer.","authors":"Sameh H Emile, Nir Horesh, Zoe Garoufalia, Rachel Gefen, Anjelli Wignakumar, Steven D Wexner","doi":"10.1002/jso.28043","DOIUrl":"https://doi.org/10.1002/jso.28043","url":null,"abstract":"<p><strong>Background: </strong>Lymphovascular invasion (LVI) is an important prognosticator in rectal cancer (RC). We aimed to determine predictors for LVI in RC and incorporate them into a predictive risk score (PRS).</p><p><strong>Methods: </strong>Case-control analysis of predictors of LVI in RC using data from a national database (2010-2019). Main outcome was LVI in RC and its predictors. Odds ratios of significant independent predictors of LVI were incorporated into a PRS.</p><p><strong>Results: </strong>55,178 patients were included (60.9% male; mean age: 61.3 years). LVI was detected in 10,446 (18.9%). Independent predictors were carcinomas that were signet-ring cell (OR: 1.98, p < 0.001), moderately differentiated (OR: 1.58, p < 0.001), poorly differentiated (OR: 3.9, p < 0.001), or undifferentiated carcinomas (OR: 4.1, p < 0.001), cN1 (OR: 1.21, p < 0.001), and cN2 (OR: 1.49, p < 0.001), stage and incorporated into a PRS (0-8). Incidence of LVI was 16.3% in the low-risk group, 27.8% in the intermediate-risk group, and 40.5% in the high-risk group (p < 0.001). The PPV of the score was 40.5%, NPV was 83.7%, accuracy was 82.4%, and specificity was 97.9%.</p><p><strong>Conclusions: </strong>High-grade adenocarcinomas, signet-ring cell carcinomas, and lymph node involvement in clinical assessment were independently associated with LVI in RC. Incorporation of these predictors into a PRS conferred high specificity and good accuracy.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142829038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Orthopedic Surgeons at Greater Risk of Malpractice Claims for Treatment of Primary Malignant Bone and Soft Tissue Tumors Compared With Metastatic Bone Disease. 与转移性骨病相比,骨科医生治疗原发性恶性骨和软组织肿瘤的医疗事故索赔风险更高。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-12 DOI: 10.1002/jso.28009
Serkan Bayram, Muhammed Oduncu, Caner Beşkoç, Yusuf Atan

Background: The aim of this study was to examine cases of malpractice litigation in primary sarcoma and metastatic bone disease in orthopedic oncology, to identify the areas in which orthopedic surgeons may be guilty of negligence, and to make them aware of this.

Methods: A comprehensive examination was conducted on all closed medical malpractice cases involving bone and soft tissue malignant tumors from 2014 to 2024. Patient demographics, histopathological diagnosis, and malpractice claims made in a variety of specialties were recorded. The inclusion and exclusion criteria of the study resulted in the inclusion of 70 cases of primary bone and soft tissue sarcoma and 36 cases of metastatic bone disease.

Results: A total of 47 primary tumors were bone sarcoma and 23 were soft tissue sarcoma. A total of 11 patients with primary sarcoma were accepted for malpractice claims, representing 16% of all cases within this category. Nevertheless, no evidence of malpractice was identified among the patients with metastatic bone disease (p = 0.012). Orthopedists (44 of 85 defendants), pathologists (14 of 85 defendants), and radiologists (7 of 85 defendants) were the most common defendants in primary sarcoma malpractice cases. Surgeons other than orthopedists (21 of 49 defendants), medical oncologists (4 of 49 defendants), and radiation oncologists (4 of 49 defendants) were the most common defendants in metastatic bone disease malpractice cases.

Conclusion: Analysis of our cases suggests that malpractice claims are more likely filed against orthopedic surgeons for the treatment of primary malignant bone and soft tissue tumors than for metastatic bone disease.

背景:本研究的目的是研究骨科肿瘤中原发性肉瘤和转移性骨病的医疗事故诉讼案例,以确定骨科医生可能有过失的领域,并使他们意识到这一点。方法:对我院2014 ~ 2024年已结案的骨软组织恶性肿瘤医疗事故进行综合分析。患者人口统计,组织病理学诊断,并在各种专业的医疗事故索赔记录。该研究的纳入和排除标准纳入了70例原发性骨和软组织肉瘤和36例转移性骨病。结果:原发性骨肉瘤47例,软组织肉瘤23例。共有11例原发性肉瘤患者因医疗事故索赔被接受,占该类别所有病例的16%。然而,在转移性骨病患者中没有发现医疗事故的证据(p = 0.012)。骨科医生(85名被告中的44名)、病理学家(85名被告中的14名)和放射科医生(85名被告中的7名)是原发性肉瘤医疗事故案件中最常见的被告。除骨科医生(49名被告中的21名)、内科肿瘤学家(49名被告中的4名)和放射肿瘤学家(49名被告中的4名)以外的外科医生是转移性骨病医疗事故案件中最常见的被告。结论:我们的病例分析表明,与转移性骨病相比,治疗原发性恶性骨和软组织肿瘤的骨科医生更容易提出医疗事故索赔。
{"title":"Orthopedic Surgeons at Greater Risk of Malpractice Claims for Treatment of Primary Malignant Bone and Soft Tissue Tumors Compared With Metastatic Bone Disease.","authors":"Serkan Bayram, Muhammed Oduncu, Caner Beşkoç, Yusuf Atan","doi":"10.1002/jso.28009","DOIUrl":"https://doi.org/10.1002/jso.28009","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to examine cases of malpractice litigation in primary sarcoma and metastatic bone disease in orthopedic oncology, to identify the areas in which orthopedic surgeons may be guilty of negligence, and to make them aware of this.</p><p><strong>Methods: </strong>A comprehensive examination was conducted on all closed medical malpractice cases involving bone and soft tissue malignant tumors from 2014 to 2024. Patient demographics, histopathological diagnosis, and malpractice claims made in a variety of specialties were recorded. The inclusion and exclusion criteria of the study resulted in the inclusion of 70 cases of primary bone and soft tissue sarcoma and 36 cases of metastatic bone disease.</p><p><strong>Results: </strong>A total of 47 primary tumors were bone sarcoma and 23 were soft tissue sarcoma. A total of 11 patients with primary sarcoma were accepted for malpractice claims, representing 16% of all cases within this category. Nevertheless, no evidence of malpractice was identified among the patients with metastatic bone disease (p = 0.012). Orthopedists (44 of 85 defendants), pathologists (14 of 85 defendants), and radiologists (7 of 85 defendants) were the most common defendants in primary sarcoma malpractice cases. Surgeons other than orthopedists (21 of 49 defendants), medical oncologists (4 of 49 defendants), and radiation oncologists (4 of 49 defendants) were the most common defendants in metastatic bone disease malpractice cases.</p><p><strong>Conclusion: </strong>Analysis of our cases suggests that malpractice claims are more likely filed against orthopedic surgeons for the treatment of primary malignant bone and soft tissue tumors than for metastatic bone disease.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813524","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Contemporary Trends in Reconstruction for Patients With Sarcoma of the Breast. 乳房肉瘤重建的当代趋势。
IF 2 3区 医学 Q3 ONCOLOGY Pub Date : 2024-12-12 DOI: 10.1002/jso.28042
Jurij Kiefer, Praneet Paidisetty, Rami A I Elmorsi, Christopher H M Nguyen, Jessie Z Yu, Kelly K Hunt, Heather A Lillemoe, Alexander F Mericli, J Bryce Olenczak

Introduction: Breast sarcomas are rare, heterogeneous malignancies often associated with prior radiation and require a multidisciplinary approach, including a comprehensive reconstruction plan. We analyzed reconstructive outcomes in a large cohort of patients with breast sarcomas and provide a contemporary treatment algorithm.

Methods: We retrospectively reviewed patients who underwent breast reconstruction after surgical treatment for breast sarcoma at our institution between January 2010 and December 2023. We analyzed patient and tumor characteristics, oncologic treatments, reconstructive approaches, and outcomes.

Results: Eighty patients underwent 81 reconstructions. The median age at diagnosis was 53 years. The most common subtypes were primary angiosarcoma (35.8%) and radiation-associated angiosarcoma (33.3%). The median follow-up was 23 months. Oncologic management was multimodal: 63.0% received preoperative chemotherapy, 59.3% received post-operative chemotherapy, 35.8% received both pre- and post-operative chemotherapy, and 34.6% received pre- or post-operative radiation therapy. Forty-three (53.1%) patients underwent total mastectomy with or without chest wall resection requiring soft-tissue reconstruction. Thirty-eight (46.9%) patients underwent formal breast reconstruction. Autologous reconstructions included local tissue rearrangement (39.5%), pedicled flaps (18.5%), regional flaps (16.0%), and free flaps (13.6%). Most patients (82.7%) underwent immediate reconstruction.

Conclusion: Breast sarcomas are managed with multimodal therapy, and most patients undergo immediate reconstruction. Autologous reconstruction remains the first choice in radiated patients, however implant-based reconstruction has increased with modern approaches. Complication rates are acceptable and similar across sarcoma subtypes. Breast reconstruction is an essential component of care for these patients and can be performed safely and with good results.

简介:乳腺肉瘤是一种罕见的异质性恶性肿瘤,通常与既往放疗相关,需要多学科治疗,包括全面的重建计划。我们分析了大量乳腺肉瘤患者的重建结果,并提供了一种现代治疗算法。方法:我们回顾性分析了2010年1月至2023年12月在我院接受乳房肉瘤手术治疗后进行乳房重建的患者。我们分析了患者和肿瘤特征、肿瘤治疗、重建方法和结果。结果:80例患者进行了81次重建。诊断时的中位年龄为53岁。最常见的亚型是原发性血管肉瘤(35.8%)和辐射相关血管肉瘤(33.3%)。中位随访时间为23个月。肿瘤治疗是多模式的:63.0%接受术前化疗,59.3%接受术后化疗,35.8%接受术前和术后化疗,34.6%接受术前或术后放疗。43例(53.1%)患者行全乳切除术,合并或不合并胸壁切除术,需要软组织重建。38例(46.9%)患者接受了正式的乳房重建。自体重建包括局部组织重排(39.5%)、带蒂皮瓣(18.5%)、区域皮瓣(16.0%)和自由皮瓣(13.6%)。大多数患者(82.7%)接受了立即重建。结论:乳房肉瘤采用多模式治疗,大多数患者立即进行重建。自体重建仍然是放射患者的首选,然而基于植入物的重建随着现代方法的增加而增加。各种肉瘤亚型的并发症发生率是可以接受的,并且相似。乳房重建是这些患者护理的重要组成部分,可以安全且效果良好。
{"title":"Contemporary Trends in Reconstruction for Patients With Sarcoma of the Breast.","authors":"Jurij Kiefer, Praneet Paidisetty, Rami A I Elmorsi, Christopher H M Nguyen, Jessie Z Yu, Kelly K Hunt, Heather A Lillemoe, Alexander F Mericli, J Bryce Olenczak","doi":"10.1002/jso.28042","DOIUrl":"https://doi.org/10.1002/jso.28042","url":null,"abstract":"<p><strong>Introduction: </strong>Breast sarcomas are rare, heterogeneous malignancies often associated with prior radiation and require a multidisciplinary approach, including a comprehensive reconstruction plan. We analyzed reconstructive outcomes in a large cohort of patients with breast sarcomas and provide a contemporary treatment algorithm.</p><p><strong>Methods: </strong>We retrospectively reviewed patients who underwent breast reconstruction after surgical treatment for breast sarcoma at our institution between January 2010 and December 2023. We analyzed patient and tumor characteristics, oncologic treatments, reconstructive approaches, and outcomes.</p><p><strong>Results: </strong>Eighty patients underwent 81 reconstructions. The median age at diagnosis was 53 years. The most common subtypes were primary angiosarcoma (35.8%) and radiation-associated angiosarcoma (33.3%). The median follow-up was 23 months. Oncologic management was multimodal: 63.0% received preoperative chemotherapy, 59.3% received post-operative chemotherapy, 35.8% received both pre- and post-operative chemotherapy, and 34.6% received pre- or post-operative radiation therapy. Forty-three (53.1%) patients underwent total mastectomy with or without chest wall resection requiring soft-tissue reconstruction. Thirty-eight (46.9%) patients underwent formal breast reconstruction. Autologous reconstructions included local tissue rearrangement (39.5%), pedicled flaps (18.5%), regional flaps (16.0%), and free flaps (13.6%). Most patients (82.7%) underwent immediate reconstruction.</p><p><strong>Conclusion: </strong>Breast sarcomas are managed with multimodal therapy, and most patients undergo immediate reconstruction. Autologous reconstruction remains the first choice in radiated patients, however implant-based reconstruction has increased with modern approaches. Complication rates are acceptable and similar across sarcoma subtypes. Breast reconstruction is an essential component of care for these patients and can be performed safely and with good results.</p>","PeriodicalId":17111,"journal":{"name":"Journal of Surgical Oncology","volume":" ","pages":""},"PeriodicalIF":2.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142813516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Surgical Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1